Search

Your search keyword '"Dou, Ke-Fei"' showing total 266 results
Start Over Author "Dou, Ke-Fei"
266 results on '"Dou, Ke-Fei"'

4. Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study)

Author

Yin, Zheng, Li, Zhi-Fan, Zhang, Wen-Jia, Zhang, Shuang, Sui, Yong-Gang, Xu, Yan-Lu, Zhang, Hai-Tao, Liu, Xiao-Ning, Qiu, Hong, Zhao, Jing-Lin, Li, Jian-Jun, Dou, Ke-Fei, Qian, Jie, Wu, Yong-Jian, and Wu, Na-Qiong

Published
2023
Full Text
View/download PDF

9. Prognostic role of lipoprotein(a) in atherosclerotic cardiovascular disease risk from a perspective on current risk stratification.

Author

Li, Sha, Liu, Hui‐Hui, Zhang, Yan, Zhang, Meng, Zhang, Hui‐Wen, Zhu, Cheng‐Gang, Wu, Na‐Qiong, Xu, Rui‐Xia, Dong, Qian, Qian, Jie, Dou, Ke‐Fei, Guo, Yuan‐Lin, and Li, Jian‐Jun

Subjects
CHINESE people, CARDIOVASCULAR diseases, ALTITUDES, PERCENTILES
Abstract

Lipoprotein(a) [Lp(a)] is an emerging predictor for atherosclerotic cardiovascular disease (ASCVD) but the association from a perspective on current risk stratification was unknown. A cohort of 9944 Chinese patients with ASCVD was recruited and refined into very‐high‐risk (VHR) and non‐VHR subgroups according to current guideline. Lp(a) plasma levels were divided by its concentration (<30, 30–50, 50–75, and ≥75 mg/dL) and percentile zones (<25th, 25–50th, 50–75th, 75–90th, ≥90th). Cardiovascular events (CVEs) occurred during an average of 38.5 months' follow‐up were recorded. We found that Lp(a) was increased with risk stratification of ASCVD increasing. Prevalence of CVEs had a significantly increasing trend with gradients of Lp(a) elevation in VHR but not in non‐VHR subgroup. The adjusted HRs (95%CIs) for CVEs were 1.75(1.25–2.46) in the highest group of Lp(a) ≥75 mg/dL compared with the group of Lp(a) <30 mg/dL as the reference in overall patients, 2.18(1.32–3.58) in VHR subgroup and 1.43(0.93–2.18) in non‐VHR subgroup, respectively. The adjusted HRs (95%CIs) at the highest grade of Lp(a) levels (≥90th) were 1.72(1.19–2.50) in overall population, 2.83(1.53–5.24) in VHR subgroup and 1.38(0.86–2.12) in non‐VHR subgroup, respectively. These findings suggested that Lp(a) might contribute more to CVEs risk in VHR subgroup of ASCVD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Association of Triglyceride Glucose-Derived Indexes with Recurrent Events Following Atherosclerotic Cardiovascular Disease

Author

Li, Sha, primary, Liu, Hui-Hui, additional, Zhang, Yan, additional, Zhang, Meng, additional, Zhang, Hui-Wen, additional, Zhu, Cheng-Gang, additional, Guo, Yuan-Lin, additional, Wu, Na-Qiong, additional, Xu, Rui-Xia, additional, Dong, Qian, additional, Dou, Ke-Fei, additional, Qian, Jie, additional, and Li, Jian-Jun, additional

Published
2024
Full Text
View/download PDF

17. Diagnostic performance of intravascular ultrasound-based fractional flow reserve in evaluating of intermediate left main stenosis

Author

SUI, Yong-Gang, primary, YANG, Cheng, additional, GUAN, Chang-Dong, additional, XU, Yan-Lu, additional, WU, Na-Qiong, additional, YANG, Wei-Xian, additional, WU, Yong-Jian, additional, DOU, Ke-Fei, additional, YANG, Yue-Jin, additional, QIAO, Shu-Bin, additional, YU, Wei, additional, XU, Bo, additional, TU, Sheng-Xian, additional, and QIAN, Jie, additional

Published
2024
Full Text
View/download PDF

18. The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension

Author

Zhang, Shuang, primary, Yin, Zheng, additional, Li, Zhi-Fan, additional, Zhang, Wen-Jia, additional, Sui, Yong-Gang, additional, Xu, Yan-Lu, additional, Zhang, Hai-Tao, additional, Liu, Xiao-Ning, additional, Qiu, Hong, additional, Zhao, Jing-Lin, additional, Li, Jian-Jun, additional, Dou, Ke-Fei, additional, Qian, Jie, additional, and Wu, Na-Qiong, additional

Published
2023
Full Text
View/download PDF

20. Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance.

Author

Li, Jian‐Jun, Dou, Ke‐Fei, Zhou, Zhi‐Guang, Zhao, Dong, Ye, Ping, Chen, Hong, Chen, Zhen‐Yue, Peng, Dao‐Quan, Guo, Yuan‐Lin, Wu, Na‐Qiong, Qian, Jie, Wang, Yilong, Sun, Yihong, Liu, Jing, Li, Jianjun, Li, Jianping, Li, Yong, Li, Yue, Wu, Naqiong, and Chen, Zhenyue

Subjects
STATINS (Cardiovascular agents), CHINESE people, GENETIC polymorphisms, DIAGNOSIS, CLINICAL medicine
Abstract

The clinical benefits of statins have well‐established and recognized worldwide. Although statins are well‐tolerated generally, however, the report of statin‐related adverse event and statin intolerance are common in China, which results in insufficient use of statins and poor adherence. The main reason may be attributed to confusions or misconceptions in the clinical diagnosis and management in China, including the lack of unified definitions and diagnostic standards, broad grasp of diagnosis, and unscientific management strategies. Based on that, this consensus carefully summarized the statin‐related gene polymorphism and statin usage issue among Chinese population, and comprehensively reviewed global research data on statin intolerance, referenced guidelines, and consensus literature on statin intolerance in foreign and different regions, proposes an appropriate and easy to implement statin intolerance definition as well as corresponding diagnostic criteria and management strategies for Chinese clinicians, in order to improve the clinical application of statin drugs and enhance the prevention and treatment level of atherosclerotic cardiovascular disease in China. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Triglyceride glucose index predicts in-hospital mortality in patients with ST-segment elevation myocardial infarction who underwent primary angiography

Author

FU, Rui, primary, ZHAO, Yan-Yan, additional, CUI, Kong-Yong, additional, YANG, Jin-Gang, additional, XU, Hai-Yan, additional, YIN, Dong, additional, SONG, Wei-Hua, additional, WANG, Hong-Jian, additional, ZHU, Cheng-Gang, additional, FENG, Lei, additional, WANG, Zhi-Fang, additional, WANG, Qing-Sheng, additional, LU, Ye, additional, DOU, Ke-Fei, additional, and YANG, Yue-Jin, additional

Published
2023
Full Text
View/download PDF

27. Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts’ Committee Of National Society Of Cardiometabolic Medicine

Author

Li, Jian-Jun, Dou, Ke-Fei, Zhou, Zhi-Guang, Zhao, Dong, Ye, Ping, Zhao, Jia-Jun, and Guo, Li-Xin

Subjects
Pharmacology, Pharmacology (medical)
Abstract

Low-density lipoprotein cholesterol (LDL-C) has been considered as the primary target for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, there are still residual cardiovascular risks in some patients even if LDL-C achieves the target level. Emerging evidence suggestes that elevated triglyceride (TG) level or triglyceride-rich lipoprotein (TRL) cholesterol (TRL-C) is one of the important components of the residual cardiovascular risks. Omega-3 fatty acids have been shown to be one of the effective drugs for reducing TG. However, its efficacy in reducing the risk of ASCVD is inconsistent in large randomized clinical trials. There is lack of consensus among Experts regarding the application of omega-3 fatty acids in cardiovascular diseases including heart failure, arrhythmia, cardiomyopathy, hypertension, and sudden death. Hence, the current consensus will comprehensively and scientifically present the detailed knowledge about the omega-3 fatty acids from a variety of aspects to provide a reference for its management of omega-3 fatty acids application in the Chinese population.

Published
2022
Full Text
View/download PDF

28. Comparison of Estimated LDL Cholesterol Equations with Direct Measurement in Patients with Angiographically Confirmed Coronary Artery Disease

Author

Shi, Boqun, primary, Wang, Hao-Yu, additional, Yin, Dong, additional, Zhu, Chenggang, additional, Feng, Lei, additional, Wang, Hongjian, additional, Jia, Lei, additional, Fu, Rui, additional, Song, Chenxi, additional, Zhou, Zhou, additional, Lin, Yahui, additional, Song, Weihua, additional, and Dou, Ke-Fei, additional

Published
2022
Full Text
View/download PDF

34. Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia

Author

Shi, Boqun, primary, Wang, Hao-Yu, additional, Liu, Jinpeng, additional, Cai, Zhongxing, additional, Song, Chenxi, additional, Jia, Lei, additional, Yin, Dong, additional, Wang, Hongjian, additional, Dou, Ke-Fei, additional, and Song, Weihua, additional

Published
2022
Full Text
View/download PDF

36. New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study

Author

Wang, Hao-Yu, primary, Dou, Ke-Fei, additional, Guan, Changdong, additional, Xie, Lihua, additional, Huang, Yunfei, additional, Zhang, Rui, additional, Yang, Weixian, additional, Wu, Yongjian, additional, Yang, Yuejin, additional, Qiao, Shubin, additional, Gao, Runlin, additional, and Xu, Bo, additional

Published
2022
Full Text
View/download PDF

37. Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions

Author

Zhang, Shuang, Li, Zhi-Fan, Shi, Hui-Wei, Zhang, Wen-Jia, Sui, Yong-Gang, Li, Jian-Jun, Dou, Ke-Fei, Qian, Jie, and Wu, Na-Qiong

Subjects
Cardiology and Cardiovascular Medicine
Abstract

AimThe aim of this study was to evaluate the relationship between renal function and low-density lipoprotein cholesterol (LDL-C) goal achievement and compare the strategy of lipid-lowering therapy (LLT) among the patients with coronary artery disease (CAD) with different renal functions.MethodsIn this study, we enrolled 933 Chinese patients with CAD from September 2020 to June 2021 admitted to the Cardiometabolic Center of Fuwai Hospital in Beijing consecutively. All individuals were divided into two groups based on their estimated glomerular filtration rate (eGFR). The multiple logistical regression analysis was performed to identify and compare the independent factors which impacted LDL-C goal achievement in the two groups after at least 3 months of treatment.ResultsThere were 808 subjects with eGFR ≥ 60 ml/min/1.73 m2 who were divided into Group 1 (G1). A total of 125 patients with eGFR 2 were divided into Group 2 (G2). The rate of LDL-C goal attainment (LDL-C P = 0.02), even though there was no significant difference in the aspect of LLT between the two groups (high-intensity LLT: 82.50% vs. 85.60% P = 0.40). Notably, in G1, the proportion of LDL-C goal achievement increased with the intensity of LLT (23.36% vs. 39.60% vs. 64.52% in the subgroup under low-/moderate-intensity LLT, or high-intensity LLT without proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (PCSK9i), or high-intensity LLT with PCSK9i, respectively, P < 0.005). In addition, in G2, there was a trend that the rate of LDL-C goal achievement was higher in the subgroup under high-intensity LLT (26.60% in the subgroup under high-intensity LLT without PCSK9i and 25.00% in the subgroup under high-intensity LLT with PCSK9i) than that under low-/moderate-intensity LLT (15.38%, P = 0.49). Importantly, after multiple regression analysis, we found that eGFR 2 [odds ratio (OR) 1.81; 95%CI, 1.15–2.87; P = 0.01] was an independent risk factor to impact LDL-C goal achievement. However, the combination strategy of LLT was a protective factor for LDL-C goal achievement independently (statin combined with ezetimibe: OR 0.42; 95%CI 0.30–0.60; P < 0.001; statin combined with PCSK9i: OR 0.15; 95%CI 0.07–0.32; P < 0.001, respectively).ConclusionImpaired renal function (eGFR 2) was an independent risk factor for LDL-C goal achievement in the patients with CAD. High-intensity LLT with PCSK9i could improve the rate of LDL-C goal achievement significantly. It should be suggested to increase the proportion of high-intensity LLT with PCSK9i for patients with CAD, especially those with impaired renal function.

Published
2022
Full Text
View/download PDF

41. Additional file 1 of Association between remnant cholesterol and verbal learning and memory function in the elderly in the US

Author

Xie, Ying-Yi, Zhao, Liang, Gao, Li-Jian, Xu, Rui-Xia, Gao, Ying, Dou, Ke-Fei, Guo, Yuan-Lin, and He, Yong-Ming

Abstract

Additional file 1: Table S1. Weighted multivariable ordinal logistic regression analysis between RC levels (log-transformed) and age-stratified quartiles of the CERAD delayed score. Table S2. Weighted multivariable ordinal logistic regression analysis between the TC/RC ratio (log-transformed) and age-stratified quartiles of the CERAD delayed score.

Published
2022
Full Text
View/download PDF

42. Additional file 1 of Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome

Author

Liu, Hui-Hui, Guo, Yuan-Lin, Zhu, Cheng-Gang, Wu, Na-Qiong, Gao, Ying, Xu, Rui-Xia, Dong, Qian, Qian, Jie, Dou, Ke-Fei, and Li, Jian-Jun

Abstract

Additional file 1: Table S1. Medications at admission and on discharge of patients with and without MACEs. Table S2. Cox regression analyses of RC, Lp(a), and hsCRP levels for predicting MACEs according to LDL-C levels. Table S3. Pearson correlation analyses of the association among RC, Lp(a), and hsCRP.

Published
2022
Full Text
View/download PDF

48. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI

Author

Wang, Hao-Yu, Gao, Run-Lin, Xu, Bo, Yang, Yue-Jin, Yin, Dong, Wang, Yang, and Dou, Ke-Fei

Abstract

The benefits and harms of dual antiplatelet therapy (DAPT) continuation with aspirin and clopidogrel beyond 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for high ischemic or bleeding risk patients remain unclear. All consecutive patients undergoing PCI were prospectively included in the Fuwai PCI Registry from January 2013 to December 2013. We evaluated 7521 patients who were at high risk for thrombotic or hemorrhagic complications and were events free at 1 year after the index procedure. “TWILIGHT-like” patients with high risk of bleeding or ischemic events were defined by clinical and angiographic criteria. The primary ischemic outcome was major adverse cardiac and cerebrovascular events [MACCE] (a composite of all-cause death, myocardial infarction, or stroke). Median follow-up duration was 2.4 years. The risk of MACCE was significantly lower in DAPT>1-year group (n = 5252) than DAPT≤1-year group (n = 2269) (1.5% vs. 3.8%; hazard ratio [HR]: 0.37; 95% confidence interval [CI]: 0.27–0.50; P < .001). This difference was largely driven by a lower risk of all-cause death. In contrast, the risk of Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding was statistically similar between the two groups (1.0% vs. 1.1%; HR: 0.80; 95% CI: 0.50–1.28; P = .346). Results were consistent after multivariable regression and propensity-score matching. Prolonged DAPT beyond 1 year after DES implantation resulted in a significantly lower rate of atherothrombotic events, including a mortality benefit, with no higher risk of clinically relevant bleeding in “TWILIGHT-like” patients who were at high-risk for ischemic or bleeding events.

Published
2021
Full Text
View/download PDF

49. Additional file 1 of Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study

Author

Peng, Jia, Liu, Ming-Ming, Liu, Hui-Hui, Guo, Yuan-Lin, Wu, Na-Qiong, Dong, Qian, Qian, Jie, Dou, Ke-Fei, Zhu, Cheng-Gang, and Li, Jian-Jun

Abstract

Additional file 1: Table S1. Correlation analysis between log-transformed PCSK9 and related-parameters in all patients (N=2293). Table S2. Multiple linear analysis of PCSK9 and coagulation-related indexes. Table S3. Cox regression analysis of PCSK9, PT-t status with MACEs. Figure S1. The flowchart of this study. PCSK9, proprotein convertase subtilisin/kexin type 9; MACEs, major adverse cardiovascular events.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results